Latest Medicine stories from Life.
In a notable move, Maryland's State Affordability Board has established a price cap on Ozempic, joining nine other states exploring similar affordability measures for prescription drugs.
The Trump administration has announced a significant expansion of its drug discount platform, TrumpRx, adding 600 generic medications through partnerships with major online pharmacies.
Researchers at the University of Connecticut have developed a microneedle patch vaccine that could address significant challenges in agricultural vaccine distribution.
As the Ebola outbreak continues in the Democratic Republic of the Congo, experts are contemplating the testing of an unapproved vaccine, given the lack of approved options.
AstraZeneca has received FDA approval for its hypertension medication, marking a significant development in the biotech sector amid ongoing discussions about FDA leadership and other industry news.
The Supreme Court's decision could complicate ongoing lawsuits from pharmaceutical companies regarding drug price negotiations.
Two advocacy groups are urging the U.K. government to reconsider regulations tied to a U.S. pharma trade deal, threatening legal action if changes are not made.
Tracy Beth Høeg's resignation from the FDA's drug center follows the recent departure of Commissioner Marty Makary, highlighting a troubling leadership gap within the agency.
This editorial explores the federal government's Vaccine Injury Compensation Program and the Countermeasures Injury Compensation Program, highlighting their history and ongoing policy discussions.
In the latest Pharmalittle update, the U.S. is applying pressure on Germany regarding drug pricing policies, alongside notable changes within the FDA and developments in biotech clinical trials.
The DOJ has accused Yale and UCLA medical schools of potentially discriminatory admissions practices against white and Asian applicants, highlighting ongoing debates about equity in education.
In a significant development, BeOne has received FDA approval for its lymphoma treatment. Meanwhile, Regenxbio is making strides in Duchenne gene therapy, among other biotech updates.
Biogen has shared mixed findings from a mid-stage trial for an Alzheimer’s treatment aimed at the tau protein, amidst other industry news.
Preliminary government data indicates a 14% decrease in drug overdose deaths in 2025, with around 70,000 fatalities reported. However, experts express concern over potential policy and drug supply changes.
Recent findings suggest a potential connection between gene therapy viruses and a tumor in a young boy, raising important questions about the safety of such treatments.
Encoded Therapeutics has alerted gene therapy firms about potential trade-offs associated with a drug designed to enhance safety, which may inadvertently reduce effectiveness.
A boy's tumor has been linked to gene therapy viruses, prompting doctors to emphasize the need for careful consideration of the rare risks versus the significant benefits of such treatments.
The recent resignation of the FDA head has raised alarms about the agency's stability, with Kyle Diamantas stepping in as acting leader during a critical time.
In a significant shift at the Food and Drug Administration, Commissioner Marty Makary is stepping down following a challenging period in leadership, with Diamantas taking over.
As competition in the telehealth sector intensifies, Hims has reported a decline in sales. The company is navigating a challenging landscape, with significant developments in the biotech field.